Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Venomous snakes

Published byLewis Gray Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1 Venomous snakes"— Presentation transcript:

1 Figure 1 Venomous snakes
Images b–h courtesy of D.A.W., University of Oxford, UK, and image i courtesy of D.J.W., University of Melbourne, Victoria, Australia Gutiérrez, J. M. et al. (2017) Snakebite envenoming Nat. Rev. Dis. Primers doi: /nrdp

2 Figure 2 Geographical distribution of the estimated number of snakebite envenomings and deaths
Gutiérrez, J. M. et al. (2017) Snakebite envenoming Nat. Rev. Dis. Primers doi: /nrdp

3 Figure 3 Toxin levels in the venom of viperids and elapids
Gutiérrez, J. M. et al. (2017) Snakebite envenoming Nat. Rev. Dis. Primers doi: /nrdp

4 Figure 4 Immunoaffinity capturing antivenomics protocol
Gutiérrez, J. M. et al. (2017) Snakebite envenoming Nat. Rev. Dis. Primers doi: /nrdp

5 Figure 5 Action of snake venom toxins on different body systems
Gutiérrez, J. M. et al. (2017) Snakebite envenoming Nat. Rev. Dis. Primers doi: /nrdp

6 Figure 6 Clinical effects of snake venoms.
Gutiérrez, J. M. et al. (2017) Snakebite envenoming Nat. Rev. Dis. Primers doi: /nrdp

Download ppt "Figure 1 Venomous snakes"

Similar presentations

 Brown snake venom contains potent toxins in venom that cause paralysis or muscle weakness. Also present are postsynaptic neurotoxins, which are less.

 Brown snake venom contains potent toxins in venom that cause paralysis or muscle weakness. Also present are postsynaptic neurotoxins, which are less.
Figure 1 Incidence and mortality of cutaneous melanoma

Figure 1 Incidence and mortality of cutaneous melanoma
Figure 3 Life expectancy at birth in all countries included

Figure 3 Life expectancy at birth in all countries included
Figure 1 Anatomy of the spinal column

Figure 1 Anatomy of the spinal column
Figure 2 The US Centers for Disease Control and

Figure 2 The US Centers for Disease Control and
Reproduced with permission from Yancy, C. W. et al. 2017

Reproduced with permission from Yancy, C. W. et al. 2017
Figure 8 Implanted devices for the management of heart failure

Figure 8 Implanted devices for the management of heart failure
Figure 4 BMI and mortality in patients with heart failure

Figure 4 BMI and mortality in patients with heart failure
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Figure 2 Global epidemiology of common Clostridium difficile ribotypes

Figure 2 Global epidemiology of common Clostridium difficile ribotypes
Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.
Figure 7 European Society of Cardiology 2016

Figure 7 European Society of Cardiology 2016
Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.
Figure 4 Cardiology is replete with examples of fractal structures

Figure 4 Cardiology is replete with examples of fractal structures
Effectiveness of A Clinical Protocol Implemented To Standardize Snakebite Management In Iran: Initial Evaluation  Seyed Mostafa Monzavi, MD, Amir Ahmad.

Effectiveness of A Clinical Protocol Implemented To Standardize Snakebite Management In Iran: Initial Evaluation  Seyed Mostafa Monzavi, MD, Amir Ahmad.
Creating A Snakebite Order Set (Blank Template Example) Customize Your Order Set to the Type of Snakebites You See and to Your Patient Population.

Creating A Snakebite Order Set (Blank Template Example) Customize Your Order Set to the Type of Snakebites You See and to Your Patient Population.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 6 Imaging methods used to study Parkinson disease

Figure 6 Imaging methods used to study Parkinson disease
Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Similar presentations

Ads by Google